65,437 trials
Healthy Volunteers
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 5.6; 0.0; 16.7; 0.0 Percentage of participants
Survivorship · Cancer · Depression, Anxiety
Primary: Participation Rate - Percentage Who Agreed to Participate — 88.9 percentage of participants
Morbid Obesity · Weight Loss
Primary: Mean Weight Loss — 13.3 Pounds
Autism Spectrum Disorder · Pervasive Developmental Disorder · ASD
Primary: Change in ASD Symptoms Social Responsiveness Scale 2 (SRS-2) Scale From Baseline to Week 8 — -39.5; -29 scores on a scale
Eosinophilic Asthma
Primary: Change From Baseline in Peripheral Eosinophil Count at Day 22 — -0.199; -0.141 10^9 cells/Liters — p=0.5703
Multiple Sclerosis
Primary: Change in Gait Velocity — 0.33; 0.01 meters/second (m/s)
Prostate Specific Antigen Screening · Asymptomatic Bacteriuria · Type 2 Diabetes
Primary: PSA Screening in Older Men — 1675; 1373 Participants
Wrinkles · Fine Lines · Crepey Skin
Primary: Evaluation of Baseline Photographs Compared to Post Treatment Images — 8 photographs graded as improved
Nicotine Administration & Dosage · E-cigarettes · Vaping
Primary: Mean Nicotine Exposure — 4.6; 9.2 ng/ml*h
Chronic Back Pain
Primary: Pain Numerical Rating Scale — 0.8; 1.1 units on a scale
Cancer · Physical Inactivity
Primary: The Number of Patients Referred Using the Secure Webform — 54 Participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With Glycosylated Haemoglobin (HbA1c) Less Than 7.0 Percentage (%) (53 Millimoles Per Mole [mmol/Mol]) at Year 1 (Yes/No) — 244; 226; 186; 236…
End Stage Renal Disease
Primary: Adherence With Proposed Interventions — 88; 90; 83; 80 Percentage of sessions
Gynecologic Cancer · Gastrointestinal Cancer
Primary: Feasibility of the BOLSTER Intervention — 73; 22 Participants
Abscess
Primary: Numerical Rating Scale (NRS) Pain Score at Baseline — 8.3; 8.1 score on a scale